MedTrace Logo

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.

Conditions

Interventions

DRUG

Azacitidine

Standard of Care Intravenous (IV) infusion

DRUG

Decitabine

Standard of Care Intravenous (IV) infusion

DRUG

Venetoclax

Standard of Care PO (By Mouth)

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Onyee Chan, MD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-07
Primary Completion
2027-10-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511882 on ClinicalTrials.gov